Literature DB >> 22669514

7-Nitro-4-(phenylthio)benzofurazan is a potent generator of superoxide and hydrogen peroxide.

Eric V Patridge1, Emma S E Eriksson, Philip G Penketh, Raymond P Baumann, Rui Zhu, Krishnamurthy Shyam, Leif A Eriksson, Alan C Sartorelli.   

Abstract

Here, we report on 7-nitro-4-(phenylthio)benzofurazan (NBF-SPh), the most potent derivative among a set of patented anticancer 7-nitrobenzofurazans (NBFs), which have been suggested to function by perturbing protein-protein interactions. We demonstrate that NBF-SPh participates in toxic redox-cycling, rapidly generating reactive oxygen species (ROS) in the presence of molecular oxygen, and this is the first report to detail ROS production for any of the anticancer NBFs. Oxygraph studies showed that NBF-SPh consumes molecular oxygen at a substantial rate, rivaling even plumbagin, menadione, and juglone. Biochemical and enzymatic assays identified superoxide and hydrogen peroxide as products of its redox-cycling activity, and the rapid rate of ROS production appears to be sufficient to account for some of the toxicity of NBF-SPh (LC(50) = 12.1 μM), possibly explaining why tumor cells exhibit a sharp threshold for tolerating the compound. In cell cultures, lipid peroxidation was enhanced after treatment with NBF-SPh, as measured by 2-thiobarbituric acid-reactive substances, indicating a significant accumulation of ROS. Thioglycerol rescued cell death and increased survival by 15-fold to 20-fold, but pyruvate and uric acid were ineffective protectants. We also observed that the redox-cycling activity of NBF-SPh became exhausted after an average of approximately 19 cycles per NBF-SPh molecule. Electrochemical and computational analyses suggest that partial reduction of NBF-SPh enhances electrophilicity, which appears to encourage scavenging activity and contribute to electrophilic toxicity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22669514      PMCID: PMC3781597          DOI: 10.1007/s00204-012-0872-9

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  39 in total

1.  The reactivity of SH groups with a fluorogenic reagent.

Authors:  D J. Birkett; N C. Price; G K. Radda; A G. Salmon
Journal:  FEBS Lett       Date:  1970-02-25       Impact factor: 4.124

2.  4-nitrobenzofurazans and 4-nitrobenzofuroxans: a new class of thiol-neutralising agents and potent inhibitors of nucleic acid synthesis in leucocytes.

Authors:  M W Whitehouse; P B Ghosh
Journal:  Biochem Pharmacol       Date:  1968-01       Impact factor: 5.858

3.  Determination of malonaldehyde precursor in tissues by thiobarbituric acid test.

Authors:  M Mihara; M Uchiyama
Journal:  Anal Biochem       Date:  1978-05       Impact factor: 3.365

4.  One- and two-electron reduction of 2-methyl-1,4-naphthoquinone bioreductive alkylating agents: kinetic studies, free-radical production, thiol oxidation and DNA-strand-break formation.

Authors:  C Giulivi; E Cadenas
Journal:  Biochem J       Date:  1994-07-01       Impact factor: 3.857

5.  Potential antileukemic and immunosuppressive drugs. II. Further studies with benzo-2,1,3-oxadiazoles (benzofurazans) and their N-oxides (benzofuroxans).

Authors:  P B Ghosh; M W Whitehouse
Journal:  J Med Chem       Date:  1969-05       Impact factor: 7.446

6.  Sensitive determination of enantiomers of amino acids derivatized with the fluorogenic reagent, 4-fluoro-7-nitro-2,1,3-benzoxadiazole, separated on a Pirkle-type column, Sumichiral OA 2500(S).

Authors:  K Imai; T Fukushima; S Uzu
Journal:  Biomed Chromatogr       Date:  1993 May-Jun       Impact factor: 1.902

7.  Bacteriostatic effect of 4,7-dicyanobenzofurazan due to inactivation of 2,3-dihydroxyisovalerate dehydratase.

Authors:  T Takabatake; M Hasegawa; T Nagano; M Hirobe
Journal:  Chem Pharm Bull (Tokyo)       Date:  1992-06       Impact factor: 1.645

8.  Effects of superoxide dismutase and catalase during reduction of adrenochrome by DT-diaphorase and NADPH-cytochrome P450 reductase.

Authors:  S Baez; J Segura-Aguilar
Journal:  Biochem Mol Med       Date:  1995-10

9.  Difference in superoxide toxicity between 4,7-dicyanobenzofurazan and paraquat.

Authors:  T Takabatake; M Hasegawa; T Nagano; M Hirobe
Journal:  J Biol Chem       Date:  1992-03-05       Impact factor: 5.157

10.  Structural basis for the binding of the anticancer compound 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol to human glutathione s-transferases.

Authors:  Luca Federici; Carlo Lo Sterzo; Silvia Pezzola; Adele Di Matteo; Flavio Scaloni; Giorgio Federici; Anna Maria Caccuri
Journal:  Cancer Res       Date:  2009-10-06       Impact factor: 12.701

View more
  8 in total

1.  Irreversible binding of an anticancer compound (BI-94) to plasma proteins.

Authors:  Nagsen Gautam; Rhishikesh Thakare; Sandeep Rana; Amarnath Natarajan; Yazen Alnouti
Journal:  Xenobiotica       Date:  2015-04-14       Impact factor: 1.908

2.  The FAD-dependent glycerol-3-phosphate dehydrogenase of Giardia duodenalis: an unconventional enzyme that interacts with the g14-3-3 and it is a target of the antitumoral compound NBDHEX.

Authors:  Marco Lalle; Serena Camerini; Serena Cecchetti; Renata Finelli; Gabriella Sferra; Joachim Müller; Giorgio Ricci; Edoardo Pozio
Journal:  Front Microbiol       Date:  2015-06-01       Impact factor: 5.640

3.  Proteomic and functional analyses reveal pleiotropic action of the anti-tumoral compound NBDHEX in Giardia duodenalis.

Authors:  Serena Camerini; Alessio Bocedi; Serena Cecchetti; Marialuisa Casella; Miriam Carbo; Veronica Morea; Edoardo Pozio; Giorgio Ricci; Marco Lalle
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2017-03-29       Impact factor: 4.077

Review 4.  Reactive Chemicals and Electrophilic Stress in Cancer: A Minireview.

Authors:  Vehary Sakanyan
Journal:  High Throughput       Date:  2018-04-27

5.  Compounds with capacity to quench the tyrosyl radical in Pseudomonas aeruginosa ribonucleotide reductase.

Authors:  Gustav Berggren; Margareta Sahlin; Mikael Crona; Fredrik Tholander; Britt-Marie Sjöberg
Journal:  J Biol Inorg Chem       Date:  2019-06-20       Impact factor: 3.358

6.  Screening and discovery of nitro-benzoxadiazole compounds activating epidermal growth factor receptor (EGFR) in cancer cells.

Authors:  Vehary Sakanyan; Marie Angelini; Mickael Le Béchec; Michèle Françoise Lecocq; Florence Benaiteau; Bénédicte Rousseau; Aram Gyulkhandanyan; Lusine Gyulkhandanyan; Cédric Logé; Eric Reiter; Christos Roussakis; Fabrice Fleury
Journal:  Sci Rep       Date:  2014-02-05       Impact factor: 4.379

7.  Rapid Diminution in the Level and Activity of DNA-Dependent Protein Kinase in Cancer Cells by a Reactive Nitro-Benzoxadiazole Compound.

Authors:  Viviane A O Silva; Florian Lafont; Houda Benhelli-Mokrani; Magali Le Breton; Philippe Hulin; Thomas Chabot; François Paris; Vehary Sakanyan; Fabrice Fleury
Journal:  Int J Mol Sci       Date:  2016-05-11       Impact factor: 5.923

8.  Activation of EGFR by small compounds through coupling the generation of hydrogen peroxide to stable dimerization of Cu/Zn SOD1.

Authors:  Vehary Sakanyan; Philippe Hulin; Rodolphe Alves de Sousa; Viviane A O Silva; Artur Hambardzumyan; Steven Nedellec; Christophe Tomasoni; Cédric Logé; Charles Pineau; Christos Roussakis; Fabrice Fleury; Isabelle Artaud
Journal:  Sci Rep       Date:  2016-02-17       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.